- Companies
- Grow Therapy
Grow Therapy Revenue, Valuation, Funding & Investors
Grow Therapy is valued at $3B as of March 2026.
Last Grow Therapy valuation
$3B
Series D · Mar 2026
Last Grow Therapy funding round
$150M
Series D · Mar 2026
Grow Therapy revenue
$1B
Series C · Apr 2024
Key investors in Grow Therapy
SignalFire
TCV
Transformation Capital
Sequoia Capital
Goldman Sachs
Menlo Ventures
About Grow Therapy
Grow Therapy is a New York-headquartered online platform connecting clients with licensed mental health providers across all 50 U.S. states. It handles credentialing, billing, and insurance claims for in-network therapists, integrating with Aetna, Cigna, Medicare, Medicaid, and UnitedHealthcare among 100-plus payers. The service delivers matched referrals, business tools, peer communities, and continuing education events to independent practitioners. Supporting thousands of therapists serving over 1 million clients, Grow Therapy raised $178 million from investors including Sequoia Capital and Goldman Sachs Alternatives.
Founded
2020
HQ
Website
Status
Privately held
Customer focus
B2C & B2B
Revenue model
Services, Commission, Subscription
Revenue
$1B (Apr 2024)
Valuation
$3B (Mar 2026)
Grow Therapy Valuation
Grow Therapy is currently valued at $3B, based on its Series D in March 2026.
The $150M round was led by Goldman Sachs Growth Equity and TCV, with participation from Menlo Ventures, SignalFire, Sequoia Capital, BCI and Transformation Capital.
Grow Therapy's valuation has moved from $3B at its Series C in April 2024 to $3B in March 2026, across 2 priced rounds.
Grow Therapy valuation by funding round
Revenue multiple| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Mar 2026 | Series D | $3B | - |
| Apr 2024 | Series C | $3B | 3.0x |
Grow Therapy Revenue
Grow Therapy's latest recorded revenue is $1B, as of its Series C in April 2024. At a $3B valuation, that implies a 3.0x revenue multiple.
Grow Therapy revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Apr 2024 | $1B | $3B | 3.0x | Series C |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
Grow Therapy Funding History
Grow Therapy has raised a total of $298M across 4 funding rounds.
Grow Therapy's first fundraising round was a $15M Series A in September 2021. The most recent completed round was a $150M Series D in March 2026.
Grow Therapy funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2026 | Series D | Goldman Sachs Growth Equity (lead); TCV (lead); Menlo Ventures; SignalFire; Sequoia Capital; BCI; Transformation Capital | $150M | $3B | - |
| Apr 2024 | Series C | Sequoia Capital (lead); Plus Capital; Lauren Holiday; SignalFire; Joe Burrow; Goldman Sachs; TCV; Lily Collins; Jrue Holiday; Anna Kendrick; Dak Prescott; Transformation Capital | $88M | $3B | Grow Therapy is a mental health platform founded in 2020 that connects patients with therapists and psychiatrists through insurance-covered services, aiming to reduce barriers like long waitlists and insurance gaps by integrating with insurers, employers, health systems, and primary care providers. The company raised $150 million in a Series D round in early March 2026, led by TCV and Goldman Sachs Alternatives (Growth Equity), with participation from new investors BCI and Menlo Ventures; existing investors Sequoia Capital, SignalFire, and Transformation Capital did not join this round despite earlier indications. Bloomberg reported a post-money valuation of $3 billion for this round, while the company confirmed approximately $1 billion in annual revenue. Since its prior $88 million Series C in April 2024 led by Goldman Sachs Alternatives, Grow Therapy has scaled significantly, facilitating seven million visits in 2025 alone (10 million lifetime total) for over two million people, achieving an 85 Net Promoter Score with 90% strongly recommending the service. The company covers 220 million lives through insurance and EAP partnerships, recently announcing a deal with Circle Medical operating in 24 states in-person and 32 digitally. Funds will expand platform capabilities, including AI integration such as the acquisition of AI scribe Tenor and launch of a patient-facing app with AI-assisted journaling to reduce provider administrative burdens. Grow Therapy's growth reflects investor confidence in its execution amid a rationalized funding market post-COVID boom, positioning it as a leader in digital mental health alongside peers like Headway and Alma (recently acquired by Spring Health). Total funding raised now stands at $328 million, with plans to further integrate mental health into primary care and employer benefits for broader accessibility. |
| Sep 2022 | Series B | TCV (lead); Transformation Capital (lead); SignalFire; Silicon Valley Bank | $45M | - | - |
| Sep 2021 | Series A | SignalFire (lead); Cold Start Ventures; CoFound Partners; What If Ventures | $15M | - | Grow Therapy raised a $15 million Series A round in 2021 with participation from SignalFire and other investors including CoFound Partners, Cold Start Ventures, and What If Ventures. SignalFire served as the lead investor for this round.[user query] The funding supported the early-stage mental health platform connecting patients with licensed providers for therapy and psychiatric care via virtual and in-person services. Subsequent rounds included a $75 million Series B in 2022 and an $88 million Series C in 2024. |
Who has invested in Grow Therapy?
19 investors have backed Grow Therapy across its funding rounds, including SignalFire, TCV, Transformation Capital, Sequoia Capital, Goldman Sachs and Menlo Ventures.
Lead investors include Goldman Sachs Growth Equity, TCV, Sequoia Capital, Transformation Capital and SignalFire.
Grow Therapy Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Sep 2021 | ||
| 3 | Lead | Sep 2022 | ||
| 3 | Lead | Sep 2022 | ||
| 2 | Lead | Apr 2024 | ||
| 1 | Participant | Sep 2021 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Sep 2021 | ||
| -- | 1 | Participant | Apr 2024 | |
| 1 | Participant | Apr 2024 | ||
This data is available for Pro users. Sign up to see all 19 Grow Therapy investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Grow Therapy
Grow Therapy has acquired 2 companies to date.
Last acquisition by Grow Therapy was on February 10th 2026. Grow Therapy acquired Tenor Therapy for undisclosed valuation.
Latest Acquisitions by Grow Therapy
| Description | Tenor Therapy is a HIPAA-compliant AI platform generating clinical therapy notes and streamlining administrative paperwork for mental health professionals. | Neosync is an open-source data synchronization and anonymization platform. The Portland-headquartered project enables real-time database replication with privacy-preserving transformations for development and testing environments. Launched in 2023, Neosync integrates with PostgreSQL, MySQL, and Snowflake, supporting enterprises in compliant data pipelines. |
| HQ Country | ||
| HQ City | - | San Francisco, CA |
| Deal Date | 10 Feb 2026 | 25 Sep 2025 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Grow Therapy acquisitions and their M&A valuation multiples. Start Free Trial | ||
Grow Therapy Competitors
Grow Therapy competitors include listed companies like Doximity and Guiyang Longmaster, and private ones like eMed, Cityblock Health, Doctolib and Clarify Health Solutions.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $2B | - | ||
| Publicly listed | $645M | $229M | $4.7B | 6.2x | ||
| Private | - | - | $5.7B | - | ||
| Private | $400M | - | $6.4B | 16.0x | ||
| Private | - | - | $1.4B | - | ||
| Publicly listed | $44M | $5M | $482M | - |
Grow Therapy Public Comps
Grow Therapy is still privately-owned, but its public comps include Privia Health, Tieto, Schrödinger, CCC Intelligent Solutions, Compass Pathways, Qingdao Baheal Medical, Ping An Healthcare, JMDC, Omnicell and ACADIA Pharmaceuticals.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.1B | $44M | 1.0x | 0.9x | 50.2x | 15.3x | |||
| $2.1B | $186M | 1.3x | 1.4x | 15.2x | 7.9x | |||
| $256M | ($96M) | 7.6x | 7.9x | (20.3x) | (14.0x) | |||
| $1.1B | $238M | 4.8x | 4.5x | 21.5x | 10.8x | |||
| - | ($293M) | - | - | (5.8x) | (8.4x) | |||
| $1.1B | $139M | 1.9x | 1.9x | 15.1x | 16.8x | |||
| $815M | $52M | 0.9x | 0.9x | 13.4x | 16.9x | |||
| $324M | $88M | 5.0x | 4.6x | 18.4x | 17.9x | |||
This data is available for Pro users. Sign up to see all Grow Therapy competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Grow Therapy
| When was Grow Therapy founded? | Grow Therapy was founded in 2020. |
| Where is Grow Therapy headquartered? | Grow Therapy is headquartered in New York City, NY, United States. |
| Is Grow Therapy publicly listed? | No, Grow Therapy is a private, VC-backed company. |
| What is Grow Therapy's valuation? | Grow Therapy was last valued at $3B in its Series D in March 2026. |
| How much funding has Grow Therapy raised? | Grow Therapy has raised $298M across 4 funding rounds. |
| What was Grow Therapy's last funding round? | Grow Therapy's last funding round was a $150M Series D in March 2026, led by Goldman Sachs Growth Equity and TCV. |
| Who are Grow Therapy's investors? | Grow Therapy's investors include SignalFire, TCV, Transformation Capital, Sequoia Capital, Cold Start Ventures, Plus Capital, Menlo Ventures, Lauren Holiday, Joe Burrow, Goldman Sachs and 9 others. |
| What is Grow Therapy's revenue? | Grow Therapy's latest recorded revenue is $1B (April 2024). |
| What is Grow Therapy's revenue multiple? | Grow Therapy's latest valuation implies a 3.0x revenue multiple ($3B valuation on $1B of revenue). |
| Which companies are comparable to Grow Therapy? | Companies comparable to Grow Therapy include eMed, Doximity, Cityblock Health, Doctolib, Clarify Health Solutions and Guiyang Longmaster. |
| How many companies has Grow Therapy acquired? | Grow Therapy has acquired 2 companies, including Tenor Therapy and Neosync. |
See companies similar to Grow Therapy
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




